Carbonic anhydrase inhibitors: Ureido and thioureido derivatives of aromatic sulfonamides possessing increased affinities for isozyme I. A novel route to 2,5-disubstituted-1,3,4-thiadiazoles via thioureas, and their interaction with isozymes I, II and IV

Journal of Enzyme Inhibition

Volumn 13, Issue 2, 1998, Pages 103-123

  Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

(Thio)ureas; 1,3,4 thiadiazole; Aromatic sulfonamide; Carbonic anhydrase; Cyanate; Isozyme I, II, IV; Isozyme specific inhibitor; Thiocyanate

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; SULFONAMIDE; THIADIAZOLE DERIVATIVE; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; OXIDATION; PRIORITY JOURNAL;

EID: 0031745463     PISSN: 87555093     EISSN: None     Source Type: Journal    
DOI: 10.3109/14756369809035830     Document Type: Article

References (60)

1. This paper is Part 48 of the series "Carbonic Anhydrase Inhibitors". Part 47: Supuran, C.T. and Clare, B.W. (1997). Eur. J. Med. Chem., in press.
2. Hewett-Emmett, D. and Tashian, F.E. (1996) Mol. Phylogenet. Evol., 5, 50-77.
3. Lakkis, M.M., Bergenhem, N.C. and Tashian, R.E. (1996). Biochem. Biophys. Res. Commun., 226, 268-272.
4. Mann, T. and Keilin, D. (1940). Nature (hand.), 146, 164-165.
5. a) Roblin, R.O. and Clapp, J.W. (1950). J. Am. Chem. Soc., 72, 4890-4892.
6. b) Miller, W.H., Dessert, A.M. and Roblin, R.O. (1950). J. Am. Chem. Soc., 72, 4893-4896.
7. a) Vaughan, J.R., Eichler, J.A. and Anderson, G.W. (1956). J. Org. Chem., 21, 700-701.
8. b) Young, R.W , Wood, K.H., Vaughan, J.R. and Anderson, G.W. (1956). J. Am. Chem. Soc., 78, 4649-4654.
9. Beasley, Y.M., Overell, B.G., Petrow, V. and Stephenson, O. (1958). J. Pharm. Pharmacol., 10, 696-705.
10. Maren, T.H. (1967). Physiol. Rev., 47, 595-782.
11. Sisson, G.M. and Maren, T.H. (1956). Fed. Proc., 15, 484-490.
12. Beyer, K.H. and Baer, J.E. (1961) Pharmacol. Rev., 13, 517-562.
13. a) Maren, T.H. (1991). In Carbonic Anhydrase - From Biochemistry and Genetics to Physiology and Clinical Medicine (F. Botré, G Gros and B.T. Storey Eds.), pp. 186-207. VCH; Weinheim.
14. b) Maren, T.H. (1995). J. Glaucoma, 4, 49-62.
15. Larson, E.B., Roach, R.C., Schoene, R.B. and Hornbein, T.F. (1982). J Am. Med. Ass., 248, 328-332.
16. a) Woodbury, D.M (1980). In Antiepileptic Drugs: Mechanisms of Action (G.H. Glaser, J.K. Penry and D M. Woodbury Eds.), pp. 617-633. Raven; New York.
17. b) Reiss, W.G. and Oles, K.S. (1996) Ann. Pharmacother , 30, 514-519.
18. Weiner, I.M (1990) In The Pharmacological Basis of Therapeutics (A.G. Gilman, T.W. Rall, A.S. Nies and P. Taylor Eds.), 8th Edition, pp. 713-732. Pergamon Press; New York.
19. Supuran, C.T. (1994). In Carbonic Anhydrase and Modulation of Physiologic and Pathologic Processes in the Organism (I. Puscas Ed.) pp 29-111. Helicon; Timisoara.
20. Supuran, C.T., Conroy, C.W. and Maren, T.H. (1996). Eur. J. Med. Chem., 31, 843-846.
21. a) Lindskog, S. and Wistrand, P.J. (1987). In Design of Enzyme Inhibitors as Drugs (M.J. Sandler and H.J. Smith Eds.), pp. 698-723 Oxford Univ. Press.
22. b) Scozzafava, A. and Supuran, C.T. (1997). Metal Based Drugs, 4, 19-26.
23. c) Mincione, G., Scozzafava, A and Supuran, C.T. (1997). Metal Based Drugs, 4, 27-34.
24. a) Sugrue, M.F. (1996). J. Ocul Pharmacol. Ther , 12, 363-376.
25. b) Hartenbaum, D. (1996). Clin Ther., 18, 460-465.
26. a) Maus, T.L., Larsson, L.I., McLaren, J.W. and Brubaker, R.F. (1997). Arch. Ophthalmol., 115, 45-49
27. b) Hetjl, A , Strahlman, E., Sverisson, T., Brinchman-Hansen, O., Pustjarvi, T. and Tipping, R. (1997). Ophthalmology, 104, 137-142.
28. c) Maren, T.H., Conroy, C.W., Wynns, G.C. and Levy, N.S. (1997). J. Ocul. Pharmacol. Ther., 13, 23-30.
29. d) Schoenwald, R.D., Deshpande, G.S., Rethwisch, D.G. and Barfknecht, C.F. (1997). J. Ocul. Pharmacol. Ther., 13, 41-59.
30. a) Supuran, C.T., Balaban, A.T., Gheorghiu, M.D., Schiketanz, A., Dinculescu, A. and Puscas, I. (1990). Rev. Roum. Chim., 35, 399-405.
31. b) Supuran, C.T., Manole, G., Dinculescu, A., Schiketanz, A., Gheorghiu, M.D., Puscas, I. and Balaban, A.T. (1992). J. Pharm. Sci., 81, 716-719.
32. c) Supuran, C.T. and Clare, B.W. (1995). Eur. J. Med. Chem., 30, 687-696.
33. d) Ilies, M.A., Iorga, B., Cristea, T., Banciu, M.D., Chiraleu, F., Scozzafava, A. and Supuran, C.T. (1997). Eur. J. Med. Chem., in press.
34. e) Supuran, C.T. and Scozzafava, A. (1997). J. Enz. Inhib., 12, 37-51.
35. Wistrand, P.J. and Lindqvist, A. (1991). In Carbonic Anhydrase -From Biochemistry and Genetics to Physiology and Clinical Medicine, (F. Botré, G. Gros and B.T. Storey Eds.), pp. 352-374. VCH; Weinheim.
36. Chapman, S.K. and Maren, T.H. (1978). Biochem. Biophys. Acta, 527, 272-276.
37. Jeffery, S., Edwards, Y. and Carter, N. (1980). Biochem. Genetics, 18, 843-849.
38. a) Northey, E.H. (1948). The sulfonamides and allied compounds, pp. 3-339. Reinhold; New York.
39. b) Crossley, M.L., Northey, E.H. and Hultquist, M.E. (1938). J. Am. Chem. Soc., 60, 2222-2224.
40. c) Scudi, J.V. (1937). J. Am. Chem. Soc., 59, 1480-1483.
41. d) Bauer, H. (1939). J. Am. Chem. Soc., 61, 613-616.
42. Forsman, C., Behravan, G., Osterman, A. and Jonsson, B.H. (1988). Acta. Chem. Scand., B42, 314-318.
43. Behravan, G., Jonasson, P., Jonsson, B.H. and Lindskog, S. (1991). Eur. J. Biochem., 198, 589-592.
44. Khalifah, R.G , Strader, D.J., Bryant, S.H. and Gibson, S.M. (1977). Biochemistry, 16, 2241-2247.
45. Nyman, P.O. and Lindskog, S. (1964). Biochim. Biophys. Acta, 85, 141-151.
46. Henderson, L.E., Henriksson, D. and Nyman, P.O. (1976). J. Biol. Chem., 251, 5457-5463.
47. Maren, T.H., Wynns, G.C. and Wistrand, P.J. (1993). Mol. Pharmacol., 44, 901-906.
48. Maren, T.H. (1960). J. Pharmacol. Exp. Ther., 130, 24-29.
49. Supuran, C.T., Manole, G., Schiketanz, A., Gheorghiu, M.D. and Puscas, I. (1991). Rev. Roum. Chim., 36, 251-255.
50. Supuran, C.T. (1995) Rev Roum. Chim., 40, 643-651
51. Cox, E.H. (1940). J. Am. Chem. Soc , 62, 743-4.
52. Walker, J. (1940). J Chem. Soc., 1304-1307.
53. Katritzky, A.R , Caster, K C., Maren, T.H., Conroy, C.W. and Bar-Ilan, A. (1987). J. Med. Chem., 30, 2058-2062.
54. Roth, J.S. and Degering, E.F (1945). J. Am. Chem. Soc., 67, 126-128.
55. a) Boggiano, B.G., Condon, S., Davies, M.T., Jackman, G.B., Overell, B.G., Petrow, V., Stephenson, O. and Wild, A.M. (1960). J. Pharm. Pharmacol., 12, 419-425.
56. b) Novello, F.C. and Sprague, J.M. (1957). J. Am Chem. Soc., 79, 2028-2029.
57. c) Maren, T.H. and Wiley, C.E. (1968). J. Med. Chem, 11, 228-232.
58. Kornis, G. (1984). In Comprehensive Heterocyclic Chemistry (A.R. Katritzky Ed ), Vol. 6, part 4B, pp. 545-578. Pergamon; New York.
59. Supuran, C.T., Briganti, F. and Scozzafava, A. (1997). J. Enz. Inhib., 12, 175-190.
60. Vidgren, J., Svensson, A. and Liljas, A. (1993). Int J Biol. Macromol., 15, 97-100.